Trials / Completed
CompletedNCT03108625
Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
Long-term, Open-label, Flexible-dose, Continuation Extension Study With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 7 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vortioxetine | Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day. |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2020-04-16
- Completion
- 2020-04-16
- First posted
- 2017-04-11
- Last updated
- 2021-06-24
Locations
31 sites across 13 countries: Bulgaria, Estonia, France, Germany, Hungary, Italy, Latvia, Poland, Russia, Serbia, South Africa, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT03108625. Inclusion in this directory is not an endorsement.